Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Biogen Idec to present new two-year data from the PLEGRIDY™ (peginterferon beta-1a) Phase III advance study at AAN annual meeting
Cyclophosphamide therapy in pediatric multiple sclerosis.
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
Self-Reported Fatigue and Energy Cost During Walking Are Not Related in Patients With Multiple Sclerosis.
Neuropsychological Aspects of Childhood Multiple Sclerosis: An Overview.
Haplotypes across the human caveolin 1 gene upstream purine complex significantly alter gene expression: Implication in neurodegenerative disorders.
Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis - a multicentre cohort study.
FDA approves clinical trial of TDI-132 (Gilenya) in ALS patients
No excess of mitochondrial DNA deletions within muscle in progressive multiple sclerosis.
160 Surgical outcomes of trigeminal neuralgia in patients with multiple sclerosis.
ER Chaperone BiP/GRP78 Is Required for Myelinating Cell Survival and Provides Protection during Experimental Autoimmune Encephalomyelitis.
High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain.
Warner Chilcott sells Vectrin product line to Medicis
The role of microbiome in central nervous system disorders.
Aquaporins: important but elusive drug targets.
Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients.
Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis.
Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses.
Humoral immune response to influenza vaccine in natalizumab-treated MS patients.
Complex molecular and functional outcomes of single versus sequential cytokine stimulation of rat microglia.
Immune cells after prolonged Natalizumab therapy: implications for effectiveness and safety.
Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study.
IgM antibody identifies good candidates for natalizumab
Progressive multifocal leukoencephalopathy: new concepts.

Pages